The Trump administration's executive order reclassifying marijuana under federal controlled substance law offers cannabis companies genuine regulatory relief - lower compliance costs, fewer research barriers, a cleaner path toward medical product development. What it does not offer is a bank loan from JPMorgan. That distinction matters enormously to an industry that has spent years cobbling together capital from credit unions, specialty lenders, and alternative financing vehicles, all at rates that reflect the sector's precarious federal standing.
What the Reclassification Actually Changes
Moving marijuana to a lower schedule under federal law is not nothing. It signals a shift in political posture, reduces certain compliance obligations that have burdened operators for years, and opens pathways for federally sanctioned research - which could, over time, support new medical cannabis products and the regulatory frameworks around them. For companies grinding through day-to-day operations with one hand tied behind their backs, that's meaningful friction removed.
The thing is, rescheduling is not legalization. Cannabis remains a controlled substance under federal law. Criminal penalties still apply to its use and distribution outside narrowly defined conditions. That legal reality is the exact foundation on which large financial institutions have built their refusal to engage with the sector - and nothing in the executive order dismantles it.
Why Big Banks Are Staying Put
The calculus for a major federally chartered bank is straightforward, if frustrating to cannabis operators. Proceeds from marijuana sales are still classified as illicit under federal law. Accepting those funds, processing transactions, or extending credit against them exposes a bank to anti-money-laundering violations and, critically, jeopardizes its FDIC-insured status. No compliance department at a large institution is signing off on that exposure based on a rescheduling order.
Samantha Gleit, a partner at Feuerstein Kulick leading the firm's debt finance and corporate restructuring practices, put it bluntly: "Rescheduling is great progress, but I do not expect it to open the lending floodgates for cannabis operators, or for it to be materially behavior-altering for larger banks." She added that until full federal legalization arrives, providing treasury services or credit to cannabis companies "will continue to be a banking hurdle, particularly for the larger institutions that need to maintain their FDIC ensured status."
Michael Ashley Schulman, chief investment officer at Running Point Capital Advisors, struck a similar note. Some regional or technology-oriented banks may edge closer to the sector, he suggested, but the major institutions aren't about to start circulating term sheets. The risk-reward calculus simply doesn't shift enough on rescheduling alone.
The SAFER Banking Act - Still the Real Answer
The American Bankers Association, representing the country's major lenders, has made its position clear: the solution is legislative, not executive. The association is calling on Congress and the administration to pass the SAFER Banking Act - the Secure and Fair Enforcement Regulation Banking Act - a bipartisan measure that would give financial institutions explicit legal protection when serving cannabis businesses operating legally under state law. Without that statutory clarity, the association's position holds: "proceeds from its sale are still considered illicit, which carries significant risks for banks that want to serve the industry."
The SAFER Banking Act has moved through congressional committees in various forms over several sessions without becoming law. Its central promise is legal certainty - the one thing banks consistently say they need before extending routine financial services to cannabis operators. Rescheduling provides neither the explicit authorization nor the liability protection the act would confer. That gap is not minor. It is the entire problem.
Capital Still Follows Clarity - and Clarity Hasn't Arrived
For operators on the ground, the optimism around reclassification is real but guarded. Ari Raptis, CEO of cannabis distributor Talaria Transportation, captured the industry's mood precisely: "From a financial standpoint, this improves a lot of optics, but not access. Capital follows clarity and clarity still hasn't arrived yet."
That sentence deserves to hang in the air for a moment. Optics. Not access. The cannabis sector has had no shortage of favorable optics over the past decade - a wave of state-level legalizations, shifting public opinion, bipartisan sympathy in Congress. What it has consistently lacked is the federal legal infrastructure that turns investor sentiment into actual credit lines, depository accounts at major institutions, and the kind of routine financial plumbing every other industry takes for granted.
Until Congress acts - or until a future administration moves toward full descheduling - cannabis companies will continue paying a premium for capital that their competitors in other industries access cheaply. The executive order is progress in the regulatory sense. As a financing event, it changes very little.
